Literature DB >> 17163773

The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication.

Tobin J Dickerson1, Kim D Janda.   

Abstract

Botulinum neurotoxins (BoNTs) are agents responsible for botulism, a disease characterized by peripheral neuromuscular blockade and subsequent flaccid paralysis. The potent paralytic ability of these toxins has resulted in their use as a therapeutic; however, BoNTs are also classified by the Centers for Disease Control and Prevention as one of the six highest-risk threat agents of bioterrorism. Consequently, a thorough understanding of the molecular mechanism of BoNT toxicity is crucial before effective inhibitors and, ultimately, an approved drug can be developed. In this article, we systematically detail BoNT intoxication by examining each of the discrete steps in this process. Additionally, rationally designed strategies for combating the toxicity of the most potent BoNT serotype are evaluated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163773     DOI: 10.1021/cb600179d

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  21 in total

1.  In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin.

Authors:  Tzuu-Wang Chang; Michael Blank; Pavithra Janardhanan; Bal Ram Singh; Charlene Mello; Michael Blind; Shuowei Cai
Journal:  Biochem Biophys Res Commun       Date:  2010-05-07       Impact factor: 3.575

2.  An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.

Authors:  Lisa M Eubanks; Mark S Hixon; Wei Jin; Sukwon Hong; Colin M Clancy; William H Tepp; Michael R Baldwin; Carl J Malizio; Michael C Goodnough; Joseph T Barbieri; Eric A Johnson; Dale L Boger; Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-09       Impact factor: 11.205

Review 3.  Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.

Authors:  A Ferrari; M Manca; V Tugnoli; L Alberto
Journal:  Funct Neurol       Date:  2018 Jan/Mar

4.  Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors Through Rational Design.

Authors:  Petr Capek; Yan Zhang; Deborah J Barlow; Karen L Houseknecht; Garry R Smith; Tobin J Dickerson
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

5.  Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization.

Authors:  Joseph S Zakhari; Isao Kinoyama; Mark S Hixon; Antonia Di Mola; Daniel Globisch; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2011-09-14       Impact factor: 3.641

6.  Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare.

Authors:  Fetweh H Al-Saleem; Zidoon Nasser; Rebecca M Olson; Linsen Cao; Lance L Simpson
Journal:  J Pharmacol Exp Ther       Date:  2011-05-17       Impact factor: 4.030

7.  The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity.

Authors:  Shuowei Cai; Paul Lindo; Jong-Beak Park; Kruti Vasa; Bal Ram Singh
Journal:  Toxicon       Date:  2009-12-07       Impact factor: 3.033

8.  Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors.

Authors:  Katerina Capková; Yoshiyuki Yoneda; Tobin J Dickerson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2007-10-09       Impact factor: 2.823

9.  Function-oriented synthesis applied to the anti-botulinum natural product toosendanin.

Authors:  Yuya Nakai; William H Tepp; Tobin J Dickerson; Eric A Johnson; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2008-12-25       Impact factor: 3.641

Review 10.  Investigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins.

Authors:  Katerina Capková; Nicholas T Salzameda; Kim D Janda
Journal:  Toxicon       Date:  2009-03-25       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.